Pediatric drug formulations: A rate-limiting step

Drug Information Journal

Volumn 33, Issue 2, 1999, Pages 393-396

  Nahata, Milap C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Desired doses; Infants and children; Pediatric drug formulations

Indexed keywords

CAPTOPRIL; MORPHINE; PHENOBARBITAL; PROPYLENE GLYCOL; SORBITOL;

CHILD; CONGESTIVE HEART FAILURE; DRUG FORMULATION; DRUG RESEARCH; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; HYPEROSMOLALITY; HYPERTENSION; INFANT; PEDIATRICS; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; REVIEW;

EID: 0033063188     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300210     Document Type: Review

References (7)

1. NIH News Alert. National Institute of Child Health and Human Development. National Institutes of Health. Bethesda, MD. November 25, 1997.
2. rd edition. Cincinnati, OH: Harvey Whitney Books Co.; 1997;1-118.
3. rd ed. Stanford, CT: Appleton & Lange; 1997; 77-86.
4. Nahata MC, Morosco RS, Hipple TF. Stability of captopril in liquid containing ascorbic acid or sodium ascorbate. Am J Hosp Pharm. 1994;51:1707-1708.
5. Trissel LA. Assay reliability. Am J Health Syst Pharm. 1998;55:491 (letter).
6. ASHP Reports. Council on Professional Affairs. Am J Health Syst Pharm. 1997;54:819-826.
7. US Department of Health and Human Services. Food and Drug Administration. 21CFR Parts 201, 312, 314, and 601. [Docket No. 97N-0165]. RIN 0910-AB20. Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients. August 17, 1997.